Iconic Therapeutics is a clinical-stage biopharmaceutical company based in San Francisco focused on retinal disease and cancer. The company's expertise lies in tissue factor (TF) biology. TF is a protein that plays a key role in inflammation and pathological angiogenesis (the formation of abnormal new blood vessels). Iconic Therapeutics is building a new class of TF therapeutics (mAB) in which the protein is overexposed, pursuing promising opportunities such as treating wet age-related macular degeneration (AMD) and certain solid tumors.
In May 2018, in the area of opthalmology, Iconic's first-generation fusion protein (ICON-1) has demonstrated target engagement, biologic activity, and the ability to impact clinical endpoints in a controlled Phase 2 trial. It is a fusion protein that binds to TF overexposed in the retina and the choroidal neovascularization (CNV) of AMD patients. The antibody is expected to enter formal IND-enabling studies in 2019.
In the area of cancer, TF overexpression on tumors, tumor vasculature, and the tumor microenvironment is a key attribute of multiple solid tumors. Iconic's propriety antibody drug conjugate (ADC), mAb targets TF without interfering with blood clotting. This ADC is expected to enter formal IND-enabling studies in 2019 as well.